Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Lung Neoplasms 14Neoplasm Metastasis 3Pleural Effusion 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Salivary Gland Neoplasms 1Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-small Cell Lung Cancer Metastatic 1Neoplasms 1Mycosis Fungoides 1Mesothelioma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 9Carboplatin 9Docetaxel 8Paclitaxel 6Nivolumab 6Cisplatin 5Gemcitabine 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4osimertinib 3fludarabine 3aldesleukin 3Radiotherapy 3Pemetrexed 3Erlotinib Hydrochloride 3Cyclophosphamide 3motexafin gadolinium 2figitumumab 2cemiplimab 2brigatinib 2atezolizumab 2alpha-2'-deoxythioguanosine 2Taxes 2Radiosurgery 2Ipilimumab 2Interleukin-2 2Crizotinib 2Bevacizumab 2vistusertib 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × vandetanib × Thoracic × Clear all
NCT00404924 2016-09-30

ZD6474 (ZACTIMAâ„¢) Phase III Study in EGFR Failures

Sanofi

Phase 3 Completed
1,140 enrolled 12 charts
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Carcinoma, Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡